The Outcome of COVID-19 Infection on Kidney Transplantation Recipients in Southern Saudi Arabia: Single-Center Experience.
Journal
Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
21
10
2022
revised:
27
11
2022
accepted:
19
12
2022
medline:
1
5
2023
pubmed:
22
1
2023
entrez:
21
1
2023
Statut:
ppublish
Résumé
To report the incidence, risk factors, and outcome of severe COVID-19 disease in kidney transplant recipients attending a Saudi hospital at a single center in the Kingdom of Saudi Arabia. A retrospective chart-based cohort study involving all kidney transplant recipients tested for COVID-19 in the Armed Forces Hospital Southern Region, KSA. Of 532 kidney transplant recipients who reported to the center, from March 2020 to June 2022, 180 were tested for COVID-19. Of these recipients, 31 (17%) tested positive. Among the 31 positive recipients, 11 were treated at home, 15 were admitted to the noncritical isolation ward, and 5 were admitted to the intensive care unit (ICU). Older age (P = .0001), higher body mass index (P = .0001), and history of hypertension (P = .0023) were more frequent in the COVID-19-positive recipients. Admission to the ICU was more frequent in older recipients (P = .0322) with a history of ischemic heart disease (P = .06) and higher creatinine baseline (P = .08) presenting with dyspnea (P = .0174), and acute allograft dysfunction (P = .002). In the ICU group, 4 (80%) patients required hemodialysis, and 4 (80%) died. Kidney transplant recipients with COVID-19 could have a higher risk for developing acute kidney injury, dialysis, and mortality than the general population. ICU admission and renal replacement therapy were more evident in older recipients with a history of ischemic heart disease, presenting with shortness of breath (P = .017) and a higher serum creatinine baseline. Acute allograft dysfunction was the independent predictor of mortality among patients admitted to the ICU.
Sections du résumé
BACKGROUND
BACKGROUND
To report the incidence, risk factors, and outcome of severe COVID-19 disease in kidney transplant recipients attending a Saudi hospital at a single center in the Kingdom of Saudi Arabia.
METHODS
METHODS
A retrospective chart-based cohort study involving all kidney transplant recipients tested for COVID-19 in the Armed Forces Hospital Southern Region, KSA.
RESULTS
RESULTS
Of 532 kidney transplant recipients who reported to the center, from March 2020 to June 2022, 180 were tested for COVID-19. Of these recipients, 31 (17%) tested positive. Among the 31 positive recipients, 11 were treated at home, 15 were admitted to the noncritical isolation ward, and 5 were admitted to the intensive care unit (ICU). Older age (P = .0001), higher body mass index (P = .0001), and history of hypertension (P = .0023) were more frequent in the COVID-19-positive recipients. Admission to the ICU was more frequent in older recipients (P = .0322) with a history of ischemic heart disease (P = .06) and higher creatinine baseline (P = .08) presenting with dyspnea (P = .0174), and acute allograft dysfunction (P = .002). In the ICU group, 4 (80%) patients required hemodialysis, and 4 (80%) died.
CONCLUSIONS
CONCLUSIONS
Kidney transplant recipients with COVID-19 could have a higher risk for developing acute kidney injury, dialysis, and mortality than the general population. ICU admission and renal replacement therapy were more evident in older recipients with a history of ischemic heart disease, presenting with shortness of breath (P = .017) and a higher serum creatinine baseline. Acute allograft dysfunction was the independent predictor of mortality among patients admitted to the ICU.
Identifiants
pubmed: 36681582
pii: S0041-1345(22)00888-0
doi: 10.1016/j.transproceed.2022.12.013
pmc: PMC9826984
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
521-529Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Br J Haematol. 2020 Jul;190(1):24-27
pubmed: 32379894
Exp Clin Transplant. 2022 Feb;20(2):130-135
pubmed: 34775943
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Ren Fail. 2020 Nov;42(1):393-397
pubmed: 32340507
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Rom J Intern Med. 2021 Mar 05;59(1):10-42
pubmed: 33155999
J Med Virol. 2021 Mar;93(3):1449-1458
pubmed: 32790106
Am J Transplant. 2020 Nov;20(11):3140-3148
pubmed: 32649791
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Transpl Immunol. 2021 Dec;69:101445
pubmed: 34384886
BMC Nephrol. 2020 Oct 1;21(1):419
pubmed: 33004002
BMJ. 2020 May 14;369:m1849
pubmed: 32409561
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Clin Infect Dis. 2021 Jul 15;73(2):328-331
pubmed: 32750119
Sci Rep. 2021 May 26;11(1):11022
pubmed: 34040117
Liver Int. 2020 Aug;40(8):1972-1976
pubmed: 32471013
J Med Virol. 2020 Sep;92(9):1449-1459
pubmed: 32242947
Am J Transplant. 2021 Mar;21(3):1285-1294
pubmed: 33252201
Infect Dis (Lond). 2020 Nov;52(11):830-837
pubmed: 32657186
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
Nat Rev Nephrol. 2020 Jul;16(7):365-367
pubmed: 32409782
Kidney Med. 2020 Jun 15;2(4):459-466
pubmed: 32775986
J Clin Virol. 2020 Jun;127:104380
pubmed: 32353761
Clin Infect Dis. 2020 Nov 19;71(16):2199-2206
pubmed: 32407459
Clin Microbiol Infect. 2021 Aug;27(8):1173.e1-1173.e4
pubmed: 33957273
Transpl Infect Dis. 2020 Dec;22(6):e13413
pubmed: 32677721
J Am Soc Nephrol. 2020 Oct;31(10):2413-2423
pubmed: 32847984
Virus Res. 2012 Apr;165(1):112-7
pubmed: 22349148
Clin Transplant. 2020 Sep;34(9):e14055
pubmed: 33439508
Clin Infect Dis. 2020 Jul 28;71(15):748-755
pubmed: 32239127
Scand J Clin Lab Invest. 2020 Oct;80(6):441-447
pubmed: 32449374
Gut. 2020 Jun;69(6):973-974
pubmed: 32273292
CEN Case Rep. 2020 Nov;9(4):409-412
pubmed: 32564306
J Med Virol. 2021 Feb;93(2):831-842
pubmed: 32672860
Transplant Proc. 2021 Oct;53(8):2438-2446
pubmed: 34275597
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Braz J Infect Dis. 2020 Jul - Aug;24(4):365-367
pubmed: 32603679
Kidney Int. 2020 Jun;97(6):1083-1088
pubmed: 32354634
Eur Urol. 2020 Jun;77(6):742-747
pubmed: 32249089
Kidney Int. 2020 Jul;98(1):209-218
pubmed: 32416116
Lancet. 2020 Oct 3;396(10256):959-967
pubmed: 32896292
Lancet Respir Med. 2020 May;8(5):e39
pubmed: 32305079
Am J Transplant. 2020 Jul;20(7):1819-1825
pubmed: 32351040
Kidney Int. 2020 Dec;98(6):1549-1558
pubmed: 32853631
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
BMJ. 2020 May 29;369:m1996
pubmed: 32471884
Clin Immunol. 2020 May;214:108393
pubmed: 32222466
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Glycobiology. 2008 Dec;18(12):1085-93
pubmed: 18818423
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):337-342
pubmed: 32202240
Am J Transplant. 2020 Nov;20(11):3030-3041
pubmed: 32777153